About the eXalt2 Study

The eXalt2 clinical study is for adults with ALK+ lung cancer who have previously received crizotinib or alectinib to treat their disease. With this study we aim to evaluate the safety of ensartinib and see how tumors of previously treated patients respond to this medication.

Find A Location Near You

About the eXalt3 Study

The eXalt3 clinical study is for adults with ALK+ lung cancer. On this study, we evaluate the safety of ensartinib compared to crizotinib (Xalkori), which is one of the current standard treatments of care, and see how tumors of patients previously untreated with an ALK inhibitor respond to this medication.

Find A Location Near You

Is an eXalt study right for me?